CVRx Stock Is Falling Overnight: Here's What's Driving the Move

CVRx Inc. (NASDAQ: CVRX ) shares plunged more than 45% after the company slashed its full-year revenue outlook despite reporting double-digit sales growth during the second quarter. 20 in overnight trading. CVRx is a commercial-stage medical device company that develops Barostim, an implantable neuromodulation therapy designed to treat patients with heart failure.

7 million, up 16% year over year. S. 8 million, while gross margin improved to 87% from 84% a year earlier. S.

implanting centers to 258 from 240 last year. 7 million, or 57 cents per share, a year earlier. 6 million in cash and cash equivalents. Despite those results, CVRx reduced its full-year 2026 outlook and now expects revenue between $58 million and $60 million.

5 million. CEO Kevin Hykes said the company was encouraged by its revenue growth and reimbursement progress but acknowledged challenges for the remainder of the year. “We are pleased with the strong revenue growth and margin performance in the second quarter along with the reimbursement progress we made… However, we are not satisfied with our updated outlook for the balance of the year, driven by fewer sales territories than anticipated, lower sales force productivity and a prolonged challenge with one of our largest payers,” Hykes said. The company also highlighted a new Medicare Advantage coverage policy from Humana Inc.

(NYSE: HUM ) for Barostim therapy that became effective in May, calling it an important reimbursement milestone. 6 million. 37. 86%.

Edge Stock Rankings show a positive short-term price trend, while the medium- and long-term price trends remain negative. Disclaimer: This content was produced with the help of AI tools and was reviewed and published editors. Read Also: Warner Bros. com